Beyond the needle: The future of intratumoral therapy
From BioSpace · · 21 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.
Host
Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace
Guests
Lewis Bender (https://www.linkedin.com/in/lewis-bender-7b5a7a7/), President & CEO, Intensity Therapeutics
Paul-Peter Tak (https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/), President, CEO and Board Director, Candel Therapeutics
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.